Grading Prostate Cancer: Recent Changes and Refinements
|
|
- Annice McCoy
- 6 years ago
- Views:
Transcription
1 USPSTF: 2012 Report on serum PSA Screening Recommendation rating of D Reduced screening, Reduced biopsies, reduced incidence Refinements currently occurring in WHY? Grading Prostate Cancer: Recent Changes and Refinements Current Issues in Pathology May 25, 2017 Eapen, et al., Curr. Op. Urol. 27(3): ( May 2017) Jeffry P. Simko, PhD, MD Professor of Clinical Pathology Departments of Urology, Radiation Oncology and Anatomic Pathology Disclosures: GenomeDx: Consultant 3D Biopsy: Advisory Board, Consultant 3 Scan: Advisory Board, Consultant Motivation: Recent adjustments to Gleason Grading for prostatic adenocarcinoma 2005 & 2014 ISUP Gleason Consensus Meetings 2014 Proposal of Prognostic Grade Groups (Gleason Grade Groups or GGG) More than half dozen outcome studies. WHO ( Blue Book ) / CAP Endorsements Future needs & adjustments? Problem areas that still exist! Correlations with molecular patterns 3D pathology and image analysis 1
2 Grading Cancers of the Prostate: Prostatic adenocarcinoma (> 99%) Acinar type atrophic, foamy, pseudohyperplastic, others Ductal type Mucinous type Vacuolated type (signet ring cell-like) Grading Systems (more than 40): Architecture vs. Cytology vs. Combinations Other carcinoma and malignant tumor types (essentially all are high grade. Many Treatment-Related?) Urothelial carcinoma Squamous cell carcinoma Small cell carcinoma Adenosquamous carcinoma Metaplastic carcinoma / carcinosarcoma and sarcomas Urol Surg Pathol 1 st Ed. (Elsevier, Bostwick & Eble: 1996) Gleason Grading: The most important tissue-based prognostic and predictive factor (WHO Blue Book, 2016) Not accepted by WHO until 2003! Predicts stage, treatment outcomes, recurrence, progression and death! Original Gleason System Formulated 60 s, validated 70 s, continued valids. Architecture alone (not cytology) Tumor heterogeneity is taken into account Grades: 1-5 based on gland growth patterns Profound effects on Management Active surveillance ( No pattern 4? ) Type of radiation? + / - Anti-androgens Adjuvant therapy post prostatectomy? Grade X + Grade Y = Score ( sum: 2-10 ) X = Most common tumor growth pattern (primary grade) Y = Second most common pattern (Secondary grade) If Y < 5% (< 3%) of total tumor, then repeat X. For Primary tumor ( Not for treated tumor or METs. ) 2
3 DF Gleason, 1966 Gleason pattern 1: Circumscribed nodule of uniform glands Uniform glands with no fusion ( fusion is 4) Never call on Bx, only RP Extremely rare, usually other patterns too Gleason Pattern 2: Regular or irregular glands in a less circumscribed nodule. No intervening benign glands (that is 3) Individual glands, no fusion (fusion is 4) 3
4 Gleason pattern 3: Individual glands infiltrating benign Irregular distribution (not uniform) Regular distribution OK if B9 incorporated 4
5 DF Gleason,
6 Gleason Pattern 4: Gland fusion Cribriform (glomerulations) Sinuating small glands in chains or cords Poorly formed glands? High grade tumor (changes Rx options) 6
7 Jesses comments. 7
8 8
9 Gleason Pattern 5: Single cells, solid sheets or necrosis in 4 Vacuoles are not pattern 4! McKenney, et al., Am J Surg Pathol 40: 1439 (2016) 9
10 10
11 More sclerotic. Dolphining McKenney, et al., Am J Surg Pathol 40: 1439 (2016) 11
12 Treated Carcinoma: Post radiation and/or anti-androgen Rx. Atrophic, associated inflammation, changes in the benign. ONLY grade if treatment changes not seen! Sometimes both treated & untreated (report). 12
13 Grading Variants: Use the Gleason growth pattern Variants and subtypes not well-defined. Classic examples, OK, BUT borders, continuum Acinar variants and subtypes. Outcome data supports this. 13
14 14
15 treated issues. 15
16 McKenney, et al., Am J Surg Pathol 40: 1439 (2016) Vacuoles all of them. 16
17 Gleason Modifications: ISUP International Society of Urologic Pathologists Consensus Meetings: 2005, 2014 Subtypes foamy, muycinous, pseudohyperplastic, atrophic. Dozens of prostate pathologists at the meetings Treating clinicians also attended the 2014 meeting Identify common areas: Consensus statements Identify areas of confusion: Experiments to clarify 2005 results criticized for no outcome data! Outcome studies have now validated virtually all Increased consistency in grading ( cribriform ) Problems with original Gleason (2005 & 2014 ISUP) Some patterns are extremely rare / not cancer? Grade 1 likely adenosis (Basal Cell IHC) Grade 2 Rare / Can t Dx on small needle Bx Not all possible growth patterns represented Inter-observer variability; degraded prognostics Some descriptions vague Cribriform 3 vs. Cribriform 4 Inter-observer variability; degraded prognostics No rules for when more than two patterns RARE 17
18 Problems with original Gleason (2005 & 2014 ISUP) Some patterns are extremely rare / not cancer Grade 1 likely adenosis Grade 2 Rare / Can t Dx on small needle Bx Some descriptions vague Cribriform 3 vs. Cribriform 4 Inter-observer variability; degraded prognostics Not all growth patterns represented (glomerulations) Inter-observer variability; degraded prognostics No rules for when more than two patterns Jesses comments. RARE 18
19 Problems with original Gleason (2005 & 2014 ISUP) Some patterns are extremely rare / not cancer Grade 1 likely adenosis Grade 2 Rare / Can t Dx on small needle Bx Some descriptions vague Cribriform 3 vs. Cribriform 4? Inter-observer variability; degraded prognostics Not all possible growth patterns represented Inter-observer variability; degraded prognostics!!! No rules for when more than two patterns Gleason Modifications: ISUP Scoring rules changed to better represent biology Bx, primary grade + worst = score, not secondary In Bx, if secondary lower grade and < 5%, ignore Prostatectomy, score discreet tumors of different grades separately. Recommend reporting percent > pattern 3. Modified Gleason -> Problems in Clinic: Grade Migration (perceived upgrading?) BEST score now 3+3 = 6 on scale Confusing to patients Difficult to explain Patient anxiety precluding conservative management Patient and clinician frustration! 3+4=7 and 4+3=7 same score, but very different outcome!!! Grade Groups: Developed by Hopkins Group (J. Epstein) No formal name yet. Endorsed by WHO: WHO Grade Groups? Gleason Grade Groups (GGG). Based on using modified Gleason grades. ISUP 2005 and ISUP 2014 consensus conferences How does this system relate to Gleason grades and patient outcomes? How to apply this reporting system to practice? 19
20 Grade Groups (Epstein): Grade Group 1 = Gleason score < 7 Grade Group 2 = Gleason score 3+4 = 7 Grade Group 3 = Gleason score 4+3 = 7 Grade Group 4 = Gleason score 8 (4+4, 3+5, 5+3) Grade Group 5 = Gleason score > 8 (4+5, 5+4, 5+5) Validated in numerous f/u studies Endorsed by WHO and CAP Data: 4+3=7 and 4+4=8 same 4+5, 5+4 same, 5+5 worse (unpubl.) How to apply Grade Groups: ISUP modified Gleason Grades works best Developed using Biopsy with highest score Subsequent study showed that using overall Bx grade group or highest Bx grade group gave similar prognosis (Berney et al., Br J Cancer Apr 21, 2016 epub) Prostatectomy: If Grade 5 > 5%, then secondary Does not strictly follow ISUP! Probably works either way. Simple translation from Gleason score to GGG Clinicians can easily translate to grade groups Keeps report cleaner / less confusion PROSTATECTOMY Pierorazio, et al. Br J Urol Int 111: (2013). Pierorazio, et al. Br J Urol Int 111: (2013). 20
21 Grade Groups (Epstein): Grade Group 1 = Gleason score < 7 Grade Group 2 = Gleason score 3+4 = 7 Grade Group 3 = Gleason score 4+3 = 7 Grade Group 4 = Gleason score 8 (4+4, 3+5, 5+3) Grade Group 5 = Gleason score > 8 (4+5, 5+4, 5+5) Berney, et al. Br J Cancer (2016) Epub doi: /bjc Simple translation from Gleason score to GGG Clinicians can easily translate to grade groups Keeps report cleaner / less confusion Improve communication with patients Will this replace Gleason? Continued Problems: Quantitative ( % of Gleason 4 and 5 ) Qualitative 3 vs. 4? (on a limited sample) Different outcomes for different types of 4? Discriminating some patterns of 4 from 5 difficult Stromal changes / cytology as a prognostic factors? 12, 000 pts. Sauter, et al., Eur Urol (Epub, 2017) 21
22 Qualitative: Expansile Cribriform Expansile Cribriform Prediction Based on Aggregate Data of Grade Group 2 Subanalyses McKenney (unpub. based on Kweldman et al., Eur J Cancer 66: 26 (2016)) Qualitative: Stromogenic Gleason 3B pattern? McKenney, et al., Am J Surg Pathol (2016) (accepted) McKenney, et al., Am J Surg Pathol 40: 1439 (2016) 22
23 McKenney, et al., Am J Surg Pathol 40: 1439 (2016) McKenney, et al., Am J Surg Pathol 40: 1439 (2016) 23
24 3 vs. 4? Decision can have major treatment implication. Active surveillance or not? Type of radiation? + / - anti-androgens. Problem areas: Tangential sectioning. Poorly formed glands. Potential aids: Level sections. Special stains: trichrome, Racemase (red chromogen). Future: 3D pathology? 24
25 25
26 3 vs. 4? Decision can have major treatment implication. Active surveillance or not? Type of radiation? + / - anti-androgens. Problem areas: Tangential sectioning. Poorly formed glands. Potential aids: Special stains: trichrome, Racemase (red chromogen). Level sections. Future: 3D pathology? 26
27 3D pathology: Light sheet microscopy (U. Washington). Summary: Improved power of Gleason Grading. Improved prognostics and consistency! Simple Grade Grouping system to improve communication with patients Areas for further improvement identified and under development. Quantifying the amount of tumor > pattern 3 (estab.) Subtyping pattern 4? Stromal characteristics and other histologic features? 3D pathology and other ancillary tools? Acknowledgements: Jesse McKenney: Cleveland Clinic Larry True: U. Washington Nick Reder: U. Washington Mike Bonham: Driver Inc. Sanjay Kakar: Brad Stohr: Karuna Garg: Nancy Greenland: 27
28 I m Hungry, let s eat Acknowledgements: Dr. Brad Stohr (MDPhD): Assistant Professor Dr. Nancy Greenland (MDPhD): Resident Physician (AP/CP) Dr. Jesse McKenney (MD): Cleveland Clinic 28
29 Epstein refs. Ductal: Tavora & Epstein, AJSP 32(7): 1060 (2008). Mucinous: Osunkoya, et al. AJSP 32(3): 468 (2008). Foamy: Nelson & Epstein, AJSP 20(4): 419 (1996). Pseudo: Humphrey, et al., AJSP 22(10): 1239 (1998). 29
30 McKenney, et al., Am J Surg Pathol 40: 1439 (2016) 30
31 DF Gleason, 1977 Gleason Modifications: ISUP Do not use Grades 1 or 2 (or use very sparingly) All carcinomas with cribriform growth = 4 Glomerulations = 4 but outcome data not in yet. Certain patterns (grades) better classified: Gleason growth pattern actually better than specific grades for some tumor morphologies. Tumor glands floating in mucin (mucinous carcinoma not all 4) Tumor with columnar cells (Ductal Ca) not always 4 Tumor cells with vacuoles seen in Gleason patterns 3, 4 or 5. Scoring rules changed to better represent biology In Bx, primary grade + worst = score, not secondary In Bx, if secondary lower grade and < 5%, ignore it. Prostatectomy, score discreet tumors of different grades separately. Recommend reporting percent tumor > pattern 3. Gleason Modifications: ISUP Do not use Grades 1 or 2 (or use very sparingly) All carcinomas with cribriform growth = 4 Glomerulations = 4 but outcome data not in yet. Certain patterns (grades) better classified: Gleason growth pattern actually better than specific grades for some tumor morphologies. Tumor glands floating in mucin (mucinous carcinoma not all 4) Tumor with columnar cells (Ductal Ca) not always 4 Tumor cells with vacuoles seen in Gleason patterns 3, 4 or 5. Scoring rules changed to better represent biology In Bx, primary grade + worst = score, not secondary In Bx, if secondary lower grade and < 5%, ignore it. Prostatectomy, score discreet tumors of different grades separately. Recommend reporting percent tumor > pattern 3. 31
32 Gleason Modifications: ISUP Do not use Grades 1 or 2 (or use very sparingly) All carcinomas with cribriform growth = 4 Glomerulations = 4 but outcome data not in yet. Certain patterns (grades) better classified: Gleason growth pattern actually better than specific grades for some tumor morphologies. Tumor glands floating in mucin (mucinous carcinoma not all 4) Tumor with columnar cells (Ductal Ca) not always 4 Tumor cells with vacuoles seen in Gleason patterns 3, 4 or 5. Scoring rules changed to better represent biology In Bx, primary grade + worst = score, not secondary In Bx, if secondary lower grade and < 5%, ignore it. Prostatectomy, score discreet tumors of different grades separately. Recommend reporting percent tumor > pattern 3. Images mucinous ductal 32
33 33
Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)
Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1) Jae Y. Ro, MD, PhD June 7, 2012 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths By Sex, United States,
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationDiagnosis, pathology and prognosis including variant pathology
PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationProstate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD
Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD Director, Genitourinary Pathology R.J. Tomsich Pathology & Laboratory Medicine Institute Professor of Pathology,
More information2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER
More information3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education
More informationPROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA
PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA 1 A good H & E helps! ADENOCARCINOMA DIAGNOSTIC CRITERIA Relatively uniform proliferation
More informationARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More information5/21/2018. Difficulty in Underdiagnosing Prostate Cancer. Diagnosis of Prostate Cancer. Evaluation of Prostate Cancer and Atypical on Needle Biopsy
Evaluation of Prostate Cancer and Atypical on Needle Biopsy Jonathan I. Epstein Difficulty in Underdiagnosing Prostate Cancer Limited tissue on needle biopsy (1 cm. x
More informationThey Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples
They Do Look Alike : in Biopsy Samples Gladell P. Paner, MD Departments of Pathology and Surgery (Urology) University of Chicago, IL USA Gladell.paner@uchospitals.edu Benign in Needle Biopsy 1. Benign
More information3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:
GU Evening Subspecialty Case Conference Rajal B. Shah, M.D. VP, Medical Director, Urologic Pathology Miraca Life Sciences, Irving, Texas Clinical Associate Professor of Pathology Baylor College of Medicine,
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationProstate cancer grading: a decade after the 2005 modified system
2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 S47 Prostate cancer grading: a decade after the 2005 modified system Jonathan I Epstein 1,2,3 1 Department of Pathology, The Johns Hopkins Medical
More informationUpdate on Reporting Prostate Cancer Pathology
Update on Reporting Prostate Cancer Pathology Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON None Disclosures Learning Objectives
More informationS1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationPathology of the Prostate. PathoBasic Tatjana Vlajnic
Pathology of the Prostate PathoBasic 24.01.17 Tatjana Vlajnic Overview Adenocarcinoma of the prostate Grading Special variants Mimickers of prostate adenocarcinoma Atrophy Inflammatory conditions Granulomatous
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationReview Article Recent advances in prostate cancer pathology: Gleason grading and beyond
Pathology International 2016; 66: 260 272 doi:10.1111/pin.12398 Review Article Recent advances in prostate cancer pathology: Gleason grading and beyond Rajal B Shah 1 and Ming Zhou 2 1 Division of Urologic
More informationDivision of Oncology, S Orsola-Malpighi Hospital, Bologna, Italy. Department of Surgery, Cordoba University Medical School, Cordoba, Spain
Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3 Daniele Minardi,1, Roberta Mazzucchelli,, Marina Scarpelli,
More informationA re-audit of Prostate biopsies from January to December 2010 and 2013.
A re-audit of Prostate biopsies from January to December 2010 and 2013. Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees Stockton on Tees. Objectives To assess and compare
More informationProstate Biopsy Interpretation: An Illustrated Guide
Prostate Biopsy Interpretation: An Illustrated Guide Authors Prostate Biopsy Interpretation: An Illustrated Guide Rajal B. Shah, M.D. Director, Urologic Pathology Caris Life Sciences 6655 North MacArthur
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationGleason grading and prognostic factors in carcinoma of the prostate
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org in carcinoma of the prostate Peter A Humphrey Department of Pathology and Immunology, Washington University School of Medicine,
More informationIn 2005, International Society of Urological Pathology
ORIGINAL ARTICLE Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen Cheng Cheng Huang, MD,*
More informationGround Glass Opacities
Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More informationUropathology January Jon Oxley
Uropathology January 2012 Jon Oxley Background to seminar These slides were available to view via the web from scanned slides The junior pathologists answered questions on them via the web The answers
More informationRecommendations for the Reporting of Prostate Carcinoma
Recommendations for the Reporting of Prostate Carcinoma Association of Directors of Anatomic and Surgical Pathology * ADASP Reporting Guidelines It has been evident for decades that pathology reports are
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More information6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).
GU Cancer Staging: Updates and Challenging Areas 13 th Current Issues in Surgical Pathology San Francisco, CA June 5, 2010 Jeffry P. Simko, PhD, MD Associate Professor Departments of Urology and Anatomic
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationProtocol for the Examination of TURP Specimens From Patients With Carcinoma of the Prostate Gland
Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Version: Prostate 4.0.4.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationProstatic ductal adenocarcinoma is a subtype of
ORIGINAL ARTICLE High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases Fabio Tavora, MD* and Jonathan I. Epstein, MD*w z Abstract:
More informationOutline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer
Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationPatient identifiers Date of request Accession/Laboratory number. CLINICAL STAGE (Note 3)
Prostate Core Needle Biopsy Histopathology Reporting Guide Part 1 - Clinical Information/Specimen Receipt Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory
More informationAlthough current American Cancer Society guidelines
ORIGINAL ARTICLE Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens Tamara L. Lotan, MD* and Jonathan I. Epstein, MD*w z Abstract: We have observed a group of
More informationProliferative Breast Disease: implications of core biopsy diagnosis. Proliferative Breast Disease
Proliferative Breast Disease: implications of core biopsy diagnosis Jean F. Simpson, M.D. Breast Pathology Consultants, Inc. Nashville, TN Proliferative Breast Disease Must be interpreted in clinical and
More informationProstatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy
Original research Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy Previn Gulavita, MD; * Shaheed W.
More informationOMPRN Pathology Matters Meeting 2017
OMPRN Pathology Matters Meeting 2017 Pathology of Aggressive Prostate Cancer Intraductal Carcinoma and Cribriform Carcinoma Dr. Michelle Downes, Staff Urologic Pathologist Sunnybrook Health Sciences Centre,
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland
Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationObjective. Atypical/Atypia. Atypical Glandular Lesions of the Prostate 12/27/2011
Atypical Glandular Lesions of the Prostate V.O.Speights,Jr.,D.O. Scott and White Memorial Hospital Texas A & M Health Science Center January 13,2012 Objective To identify histological abnormalities in
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationProtocol for the Examination of Biopsy Specimens From Patients With Carcinoma of the Prostate Gland
Protocol for the Examination of Biopsy Specimens From Patients With Carcinoma of the Prostate Gland Version: ProstateBiopsy 4.0.3.1 Protocol Posting Date: February 2019 Accreditation Requirements The use
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More information6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies
Outline of Talk Lobular Breast Cancer: Common Problems in Diagnosing LCIS in Core Biopsies Definition of lobular differentiation Variants of LCIS that: carry risk for unsampled invasive cancer mimic DCIS
More informationMacro- and microacinar proliferations of the prostate
Macro- and microacinar proliferations of the prostate (with emphasis on cancer mimics) Rodolfo Montironi, MD (IT), FRCPath (UK), IFCAP (USA) Polytechnic University of Marche Region (Ancona) School of Medicine,
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationProcedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy
Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationAlthough partial atrophy is one of the most common
ORIGINAL ARTICLE Partial Atrophy on Prostate Needle Biopsy Cores: A Morphologic and Immunohistochemical Study Wenle Wang, MD, PhD,* Xinlai Sun, MD,w and Jonathan I. Epstein, MD*zy Abstract: Partial atrophy
More informationBAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES
BAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES Lurdes Y. T. Inoue, PhD Professor Department of Biostatistics University of Washington
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationGOBLET CELL CARCINOID
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationThe 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
More informationBreast Pathology. Breast Development
Breast Pathology Lecturer: Hanina Hibshoosh, M.D. Reading: Kumar, Cotran, Robbins, Basic Pathology, 6th Edition, pages 623-635 Breast Development 5th week - thickening of the epidermis - milk line 5th
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationPathological Classification of Hepatocellular Carcinoma
3 rd APASL Single Topic Conference: HCC in 3D Pathological Classification of Hepatocellular Carcinoma Glenda Lyn Y. Pua, M.D. HCC Primary liver cancer is the 2 nd most common cancer in Asia HCC is the
More informationISPUB.COM. Interpretation Of Prostatic Biopsies: A Review. A Chitale, S Khubchandani INTRODUCTION NON-NEOPLASTIC LESIONS GRADING: GLEASON'S SCORE
ISPUB.COM The Internet Journal of Urology Volume 3 Number 1 A Chitale, S Khubchandani Citation A Chitale, S Khubchandani.. The Internet Journal of Urology. 2004 Volume 3 Number 1. Abstract The incidence
More informationUpdate on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017
Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols
More informationSalivary Glands 3/7/2017
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
More informationLYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR
BREAST LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR HISTOLOGY LOBE: (10 in whole breast) LOBULE: (many per lobe) ACINUS/I, aka ALVEOLUS/I: (many per lobule) DUCT(S): INTRA- or
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationDiagnostic Utility of Immunohistochemical Markers in Prostate Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 3 Ver. IX (March. 2017), PP 22-28 www.iosrjournals.org Diagnostic Utility of Immunohistochemical
More informationColon and Rectum: 2018 Solid Tumor Rules
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent
More informationUpdate on Prostate Pathology. Adeboye O. Osunkoya, MD. Departments of Pathology and Urology, Emory University School of Medicine.
1 Update on Prostate Pathology. Adeboye O. Osunkoya, MD Departments of Pathology and Urology, Emory University School of Medicine and Emory Winship Cancer Institute, Atlanta, GA. adeboye.osunkoya@emory.edu
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES
ASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES I. E. PLEŞEA*, B. ZAHARIA*, S. D. ENACHE**, G. MITROI***, P. TOMESCU***, O. T. POP*, P. BADEA****, A. KOŻOKIĆ***** *Department
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationMuhammad Kashif Baig, Usman Hassan and Samina Mansoor
ORIGINAL ARTICLE Role of p63 in Differentiating Morphologically Ambiguous Lesions of Prostate Muhammad Kashif Baig, Usman Hassan and Samina Mansoor ABSTRACT Objective: To observe the role of p63 staining
More informationHistological Typing Of Cancer And Precancer Of The Oral Mucosa
Histological Typing Of Cancer And Precancer Of The Oral Mucosa 1 / 7 2 / 7 3 / 7 Histological Typing Of Cancer And Within the last decade, histologic grading has become widely accepted as a powerful indicator
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationPROGNOSTIC ROLE OF NEW CONTEMPORARY GRADING SYSTEM IN PROSTATE CANCER
ejpmr, 2016,3(9), 243-250. Lakkarasu et al. SJIF Impact Factor 3.628 Research Article EUROPEAN JOURNAL OF European PHARMACEUTICAL Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH ISSN
More information